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membrane; and (iii) analysis of the dose–effect observed in
heterozygous Aqp1/þ mice.2 Dr Liakopoulos also men-
tions preliminary data showing that inhibition of AQP1 by
HgCl2 in isolated parietal sheep peritoneum is associated
with modifications of the transmesothelial resistance,
suggesting an interaction between AQP1 and other solute
transporters. However, such data should be interpreted
with caution because the use of Ussing chambers on leaky
membranes such as the peritoneum is prone to many
artifacts and because the application of HgCl2 in vitro is
associated with toxic and nonspecific effects including
increased membrane leakiness.4 Also, the fact that sodium
channels are upregulated in the renal tubular cells of
Aqp1/ mice, probably reflecting the severe concentrating
defect,5 should not be generalized. The transport of water
and solutes across the peritoneum is completely passive,
and only challenged when an osmotic gradient is created in
the peritoneal cavity. This is different from the situation in
kidney tubules, in which solute transport occurs by active
or secondary active processes.
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To the Editor: Focal segmental glomerulosclerosis (FSGS)
recurs after transplantation in 30% of cases and is associated
with nephrotic syndrome and accelerated graft loss. The
pathogenesis of recurrent FSGS is not yet fully characterized,
where glomerular permeability factors (GPF) are suspected to
play a central role.1 Mutations in genes encoding proteins of
the glomerular filtration barrier have been reported in
familial and sporadic forms of FSGS.1–3 While patients with
podocin mutations can present recurrence of FSGS after
kidney transplantation, even if with a lower incidence,1
autosomal-dominant forms are considered non-recurrent
diseases.4 We describe a patient affected by autosomal-
dominant FSGS who presented biopsy-proven recurrence
after kidney transplantation. The pedigree structure is shown
in Figure 1. The patient was diagnosed with FSGS at the age
of 21, started hemodialysis 5 years after diagnosis and
received cadaveric kidney transplantation at the age of 27.
Standard immunosuppressive therapy was started. One
year after transplantation, a full-blown nephrotic syndrome
with 4 g/day of proteinuria occurred. Kidney biopsy
showed early-stage FSGS, characterized by segmental glo-
merular areas of sclerohyalinosis with rare adhesions of the
tuft to the Bowman’s capsule at the light microscopy and
absence of immune deposits at immunofluorescence and
electron microscopy. The GPF before transplant and at the
time of recurrence were negative. Angiotensin-converting
enzyme inhibitor and angiotensin-1 receptor antagonist
therapy were started and proteinuria decreased below the
nephrotic range.
This report demonstrates the complex determination of
recurrent FSGS. In fact, if recurrence in autosomal-recessive
forms is difficult to explain, in dominant forms it is even
more complex. This is the second reported case of recurrent
autosomal-dominant FSGS,4 in which the absence of GPF
suggests an unknown mechanism of pathogenesis.
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Figure 1 | Pedigree structure. Squares represent males and circles
represent females. The index case is indicated by the arrow.
The presence of affected individuals in different generations and
the absence of consanguinity make the recessive inheritance unlikely,
the male-to-male transmission rules out the X-linked model, making
more consistent an autosomal-dominant mode of inheritance.
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